A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3)
Clinical Trial Grant
Awarded By
Celgene Corporation
Start Date
September 30, 2019
End Date
October 14, 2024
Awarded By
Celgene Corporation
Start Date
September 30, 2019
End Date
October 14, 2024